Friday, July 16, 2010

Glaxo sees $2.4 billion charge for Avandia and Paxil

The company is trying to "put the Avandia litigation issue behind [it] before earnings and get the story as clean as possible going forward," Mark Clark, an analyst at Deutsche Bank AG in London, said in a telephone interview.

"Most people are going to say this settles a substantial portion of their litigation and say it's a positive, and some will balk at the size of the charge," Mr. Clark said. "By any standard, $2.4 billion is a big charge for a quarter."

Indeed!!

Posted via email from Jack's posterous

No comments: